» Articles » PMID: 37761830

Whole-Exome Sequencing Reveals High Mutational Concordance Between Primary and Matched Recurrent Triple-Negative Breast Cancers

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2023 Sep 28
PMID 37761830
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Triple-negative breast cancer (TNBC) is a molecularly complex and heterogeneous breast cancer subtype with distinct biological features and clinical behavior. Although TNBC is associated with an increased risk of metastasis and recurrence, the molecular mechanisms underlying TNBC metastasis remain unclear. We performed whole-exome sequencing (WES) analysis of primary TNBC and paired recurrent tumors to investigate the genetic profile of TNBC.

Methods: Genomic DNA extracted from 35 formalin-fixed paraffin-embedded tissue samples from 26 TNBC patients was subjected to WES. Of these, 15 were primary tumors that did not have recurrence, and 11 were primary tumors that had recurrence (nine paired primary and recurrent tumors). Tumors were analyzed for single-nucleotide variants and insertions/deletions.

Results: The tumor mutational burden (TMB) was 7.6 variants/megabase in primary tumors that recurred ( = 9); 8.2 variants/megabase in corresponding recurrent tumors ( = 9); and 7.3 variants/megabase in primary tumors that did not recur ( = 15). was the most frequently mutated gene in all groups. Mutations in and were more common in our dataset. No alterations in were detected in our dataset.

Conclusions: We found similar mutational profiles between primary and paired recurrent tumors, suggesting that genomic features may be retained during local recurrence.

Citing Articles

Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting.

Olsson E, Lindman H, Digkas E, Thurfjell V, Ali H, Kruger U Breast. 2025; 79:103874.

PMID: 39778370 PMC: 11761257. DOI: 10.1016/j.breast.2025.103874.


The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.

Aguilar-Mahecha A, Alirezaie N, Lafleur J, Bareke E, Przybytkowski E, Lan C Genes (Basel). 2024; 15(1).

PMID: 38254917 PMC: 10815241. DOI: 10.3390/genes15010027.

References
1.
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

2.
Van Allen E, Wagle N, Stojanov P, Perrin D, Cibulskis K, Marlow S . Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014; 20(6):682-8. PMC: 4048335. DOI: 10.1038/nm.3559. View

3.
Klug T, Bast Jr R, Niloff J, Knapp R, Zurawski Jr V . Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 1984; 44(3):1048-53. View

4.
Bonin S, Hlubek F, Benhattar J, Denkert C, Dietel M, Fernandez P . Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Arch. 2010; 457(3):309-17. PMC: 2933807. DOI: 10.1007/s00428-010-0917-5. View

5.
Pascual J, Turner N . Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019; 30(7):1051-1060. DOI: 10.1093/annonc/mdz133. View